4 Biotechs That Could Explode Or Crash In May
The month of May isn’t usually a good one for the overall market. Though a handful of familiar names somehow muster bullishness in the month, the S&P 500’s average performance for the May is a loss of 0.2%.
As it turns out, however, not only do some stocks manage to thrive as the summer doldrums begin, some groups of stocks generally pick up the pace around this time of year.
Among the most surprising winners are pharmaceutical stocks, and biotech stocks in particular. Not only does the typical biotech name advance to the tune of 2% this month, May marks the beginning of an average 10.6% rally that usually doesn’t end up stopping until early September. Go figure.
As it turns out, however, not only do some stocks manage to thrive as the summer doldrums begin, some groups of stocks generally pick up the pace around this time of year.
Among the most surprising winners are pharmaceutical stocks, and biotech stocks in particular. Not only does the typical biotech name advance to the tune of 2% this month, May marks the beginning of an average 10.6% rally that usually doesn’t end up stopping until early September. Go figure.